Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15987017 | 0.84 | — | — | |
| SCHEMBL16659518 | 0.82 | KDM4E (0.32) | KDM4EPKM | |
| SCHEMBL30720 | 0.79 | KDM4E (0.33) | KDM4EPKM | |
| SCHEMBL19455050 | 0.79 | PRMT1 (0.32) | KDM4EPKM | |
| SCHEMBL19454920 | 0.79 | PRMT1 (0.32) | KDM4EPKM | |
| SCHEMBL19455053 | 0.79 | PRMT1 (0.32) | KDM4EPKM | |
| SCHEMBL24309070 | 0.78 | KDM4E (0.32) | KDM4EPKM | |
| SCHEMBL13380860 | 0.76 | CYP1A2 (0.33) | KDM4EPKM | |
| SCHEMBL3021931 | 0.76 | — | — | |
| SCHEMBL16604736 | 0.74 | KDM4E (0.37) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044183-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| EP-4310084-A1 | PYRIDOPYRIMIDINE-BASED COMPOUND AND APPLICATION THEREOF | Jinan University (CN) | 2024-01-24 | — | — | EP | disclosed |
| EP-4245756-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| EP-4209485-A1 | COMPOUND HAVING ANTITUMOR ACTIVITY AND USE THEREOF | Innovstone Therapeutics Limited (CN) | 2023-07-12 | — | — | EP | disclosed |
| WO-2023125708-A1 | P38 MAPK/MK2 PATHWAY MODULATOR, COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海美悦生物科技发展有限公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023122581-A2 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20230165867-A1 | IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF | KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230165867-A1 | IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF | KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| WO-2023076237-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2017062581-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-04-13 | — | — | WO | disclosed |
| US-9226923-B2 | Spirocyclic molecules as protein kinase inhibitors | NANJING ALLGEN PHARMA CO. LTD. (CN) | 2016-01-05 | — | — | US | disclosed |
| WO-2015172747-A1 | SPIROCYCLIC MOLECULES AS MTH1 INHIBITORS | WANG ZHAOYIN (CN) | 2015-11-19 | — | — | WO | disclosed |
| US-20140243303-A1 | SPIROCYCLIC MOLECULES AS PROTEIN KINASE INHIBITORS | BETA PHARMA CANADA INC. (CA) | 2014-08-28 | — | — | US | disclosed |
| EP-1237983-B1 | POLYMERIZABLE COMPOSITION, CURED MATERIAL THEREOF AND METHOD FOR MANUFACTURING THE SAME | SHOWA DENKO KK (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-6783840-B2 | FOR PRODUCING PRINTED CIRCUIT BOARD | SHOWA DENKO K.K. (JP) | 2004-08-31 | — | — | US | disclosed |
| US-20030022958-A1 | Resist ink composition | SHOWA DENKO K.K. (JP) | 2003-01-30 | — | — | US | disclosed |
| US-20020161068-A1 | Polymerizable composition, cured material thereof and method for manufacturing the same | SHOWA DENKO K.K. (JP) | 2002-10-31 | — | — | US | disclosed |
| EP-1222496-A1 | RESIST INK COMPOSITION | Showa Denko K.K. (JP) | 2002-07-17 | — | — | EP | disclosed |
| WO-2002008347-A2 | RESIST INK COMPOSITION | SHOWA DENKO K. K. (JP) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | KDM4E 2721/4885PKM 401/4885 |
| US-20230165867-A1 | IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF | SYMPK, PAICS, CYP2C9 | KDM4E 3146/4885PKM 72/4885 |
| US-20140243303-A1 | SPIROCYCLIC MOLECULES AS PROTEIN KINASE INHIBITORS | MET, RET, ALK | KDM4E 1118/4885PKM 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.